What is appropriate neoadjuvant/adjuvant androgen deprivation for high-risk/locally advanced prostate cancer?

Affiliations

¹ Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Ishikawa 920-8640, Japan. namiki1@kenroku.kanazawa-u.ac.jp

Comment

Mikio Namiki et al. Asian J Androl. 2011 Jul.

. 2011 Jul;13(4):624-5.

doi: 10.1038/aja.2011.74. Epub 2011 Jun 6.

¹ Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Ishikawa 920-8640, Japan. namiki1@kenroku.kanazawa-u.ac.jp

No abstract available

Comment on

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C. Denham JW, et al. Lancet Oncol. 2011 May;12(5):451-9. doi: 10.1016/S1470-2045(11)70063-8. Lancet Oncol. 2011. PMID: 21440505 Clinical Trial.

1. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004;22:2141–9. - PMC - PubMed
1. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–74. - PubMed
1. Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer. 2006;107:1265–72. - PubMed
1. Zietman AL, Shipley WU. Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy. Int J Radiat Oncol Biol Phys. 1997;37:245–6. - PubMed
1. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26:2497–504. - PubMed